We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Prader-Willi

News List

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome firstwordpharma
July 07, 2021
Soleno today provided an update following a recent interaction with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi Syndrome (PWS).
Soleno's drug misses key goal in Prader-Willi trial pharmatimes
June 10, 2020
Soleno Therapeutics has unveiled new data showing that its diazoxide choline controlled release (DCCR) tablets failed to reduce hyperphagia – or an abnormal desire for food – in patients with Prader-Willi syndrome.
Saniona Cleared to Continue Phase II Prader-Willi Syndrome Treatment Program biospace
April 27, 2018
Saniona announced it has been cleared to initiate the second part of a mid-stage trial to develop a treatment for adolescents with Prader-Willi Syndrome.